Advertisement


Fred R. Hirsch, MD, PhD, and Paul A. Bunn, Jr., MD, on the Highlights of the World Conference on Lung Cancer

2015 IASLC World Conference on Lung Cancer

Advertisement

Fred R. Hirsch, MD, PhD, of the University of Colorado Health Science Center, and Paul A. Bunn, Jr, MD, of the University of Colorado Cancer Center, give their views on the goals and important presentations of the 2015 World Conference on Lung Cancer.



Related Videos

Lung Cancer

Silvia Novello, MD, PhD: Lung Cancer Is a Women's Disease Too

Silvia Novello, MD, PhD, of the University of Turin, discusses a much-neglected aspect of lung cancer: It is not just the province of men; women are affected in great numbers as well.

Lung Cancer

James L. Mulshine, MD, on Lung Cancer Screening in the United States: Can It Happen?

James L. Mulshine, MD, of Rush University Medical Center, discusses the profound challenges of implementing national CT screening to ensure delivery of high-quality, best-practice early lung cancer detection in the target population of tobacco-exposed individuals (Abstract MS 15.01).

Lung Cancer

Heather A. Wakelee, MD, on Results of the E1505 Clinical Trial

Heather A. Wakelee, MD, of Stanford University discusses the study that explored the question of whether adding bevacizumab to adjuvant chemotherapy is beneficial in the setting of resected non–small cell lung cancer (Abstract PLEN04.03).

Lung Cancer

Jennifer King, PhD: Scientific Perspectives From the Lung Cancer Alliance

Jennifer King, PhD, of the Lung Cancer Alliance, gives her perspective on major themes of this year’s meeting: the stigma of lung cancer, the changing face of who is affected, early detection, and advances in immunotherapy.

Lung Cancer

Karen Kelly, MD, on PD-1 Axis Inhibition and the Treatment of Advanced Disease

Karen Kelly, MD, of the University of California, Davis, summarizes three important papers on NSCLC: expression as a predictive biomarker; pembrolizumab, immune-mediated adverse events, and corticosteroid use; and an evaluation of disease-related symptoms in patients treated with nivolumab or docetaxel (Abstracts ORAL 31.01, 31.02, and 31.03).

Advertisement

Advertisement




Advertisement